Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Western New England Bancorp SVP & Chief Risk Officer Leo R. Sagan Jr. Sells $47.5K of Stock
Leo R. Sagan Jr., SVP & Chief Risk Officer, sold 3,490 shares of Western New England Bancorp, Inc. at $13.61 a share, worth $47.5K in total on Sep 10, 2026. Shares held after the trade: 59,264 (-5.6%).
PDS Biotechnology completed the initial closing of a PIPE financing led by Nant Capital, raising $11.3 million in gross proceeds through the sale of common stock and warrants. The company also announced a contingent milestone closing for an additional $11 million and appointed Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. Proceeds will be used to repay $4.6 million in debt to Yorkville and advance the PDS0301 clinical program.
First Citizens BancShares filed an 8-K reporting material modifications to the rights of security holders and amendments to its Articles of Incorporation or Bylaws. These items typically indicate changes to the company's capital structure, such as the authorization of new classes of stock or changes to shareholder voting rights. Without specific document text, the filing represents a structural corporate governance update.
Sionna Therapeutics approved a restructuring plan to focus resources on its SION-451 and SION-2222 dual combination program, involving a 46% workforce reduction and the wind-down of its SION-719 add-on program. The company expects to incur approximately $6.4 million in restructuring charges, primarily for severance and contract close-out costs, while extending its cash runway into the second half of 2029. Additionally, Chief Business Officer Caroline Stark Beer was terminated without cause as part of the reorganization.
Magnolia Oil & Gas Signs $2.57B M&A Deal with WildFire Energy I LLC
Magnolia Oil & Gas Corporation completed its acquisition of WildFire Energy I LLC for $2.57 billion in cash and 32,203,000 shares of Class A common stock. As part of the transaction, Magnolia assumed $600 million in 7.500% Senior Notes due 2029 and merged the target entities into its operating subsidiary.
Curbline Properties Director Alexander Otto Sells $69.2K of Stock
Alexander Otto, Director, sold 2,344 shares of Curbline Properties Corp. at $29.51 a share, worth $69.2K in total on Sep 10, 2026. Shares held after the trade: 6,550,914 (-0.0%).
Burford Capital's subsidiary announced a private offering of $300 million in senior secured notes due 2029. The proceeds are intended to fund the redemption of $400 million in outstanding 6.250% senior notes due 2028 as part of a broader de-leveraging strategy.
Lithia Motors Insider Congdon Stacy Loretz Sells $27.8K of Stock
Congdon Stacy Loretz sold 75 shares of Lithia Motors Inc at $370.73 a share, worth $27.8K in total on Sep 11, 2026. Shares held after the trade: 2,300 (-3.2%).
La-Z-Boy President, Retail Robert Sundy II Sells $154K of Stock
Robert Sundy II, President, Retail, sold 5,000 shares of La-Z-Boy Inc at $30.85 a share, worth $154K in total on Sep 10, 2026. Shares held after the trade: 59,297 (-7.8%).
Boot Barn Holdings announced its participation in the Goldman Sachs Global Consumer and Retail Conference and the Piper Sandler Growth Frontiers Conference. The company provided a business update noting 2% same-store sales growth in fiscal August and September to date, and reaffirmed its Q2 guidance while expecting total sales and EPS to hit the high end of previously announced ranges.
Veracyte Signs $150M M&A Deal with Convergent Genomics Inc.
Veracyte completed the acquisition of Convergent Genomics, a genomic diagnostics company focused on bladder cancer, for $150 million in upfront cash plus up to $30 million in milestone-based payments. The deal adds the UroAmp urinary tumor DNA (utDNA) technology to Veracyte's urology portfolio, with a commercial launch expected in late 2028.
Value
$150M
Counterparty
Convergent Genomics Inc.
“UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”
Marc Stapley, Veracyte’s chief executive officer
“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”
Brian Slingerland, chief executive officer, Convergent Genomics
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.
Diamondback Energy Insider Travis D. Stice Sells $15.3M of Stock
Travis D. Stice sold 75,000 shares of Diamondback Energy, Inc. at $204.31 a share, worth $15.3M in total on Sep 11, 2026. Shares held after the trade: 49,727 (-60.1%).
Jushi Holdings Insider Denis J. Arsenault Buys $69.6K of Stock
Denis J. Arsenault bought 118,034 shares of Jushi Holdings Inc. at $0.59 a share, worth $69.6K in total on Sep 3, 2026. Shares held after the trade: 7,795,933 (+1.5%).
Teva Pharmaceutical Industries Ltd. has transitioned its listing on the New York Stock Exchange from American depositary shares (ADSs) to ordinary shares under the existing ticker 'TEVA'. The company's ADS program was terminated effective September 14, 2026, with each ADS exchanged for one ordinary share on a one-for-one basis.
60 Degrees Pharmaceuticals submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher (CNPV) for its ARAKODA (tafenoquine) efficacy supplement for babesiosis. The company aims to submit a supplemental New Drug Application (sNDA) in early 2027, potentially making it the first FDA-approved treatment for the tick-borne disease. An interim analysis of its randomized controlled trial is scheduled for October 1, 2026.
Oxford Square Capital $15M Debt Financing with U.S. Bank Trust Company, National Association
Oxford Square Capital Corp. has elected to redeem $15.0 million in aggregate principal amount of its 5.50% Notes due 2028. The redemption is scheduled for October 14, 2026, at a price of $25 per note plus accrued and unpaid interest. This partial redemption reduces the outstanding principal of these notes from $80.5 million to $65.5 million.
INmune Bio, Inc. has expanded its Board of Directors to seven members and appointed R. Duane Clark II and James Sapirstein as independent directors. Mr. Clark currently leads Sanofi's U.S. Rare Diseases business, while Mr. Sapirstein is the CEO of Cocrystal Pharma and has extensive experience in biopharma business development and licensing. These appointments are intended to strengthen the company's commercialization planning for Ebstrocel and its strategic partnering capabilities.
Scienture Holdings, Inc. has posted a revised investor presentation to its corporate website and filed it as an exhibit to this 8-K. The company intends to use the presentation in upcoming meetings with analysts and potential investors to discuss its projects, financial performance, and growth opportunities.
Benitec Biopharma reported financial results for the fiscal year ended June 30, 2026, ending the period with approximately $180 million in cash. The company provided a clinical update on its BB-301 program for OPMD-related dysphagia, noting that Cohort 2 is fully enrolled and a pivotal study is planned for initiation in mid-2027 following a Type C meeting with the FDA.
Term
FY2026
“This has been an important year of clinical execution for Benitec and for the continued development of BB-301. Over the course of the year, we completed the follow-up of all six patients in Cohort 1 and fully enrolled Cohort 2, while continuing the regulatory interactions required to prepare BB-301 for advancement into a pivotal trial.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
“The consistency and durability of the clinical benefit observed to date, together with the discussions we have had with the FDA regarding pivotal study plans, continue to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
NextNRG, Inc. implemented a 1-for-10 reverse stock split of its common stock effective September 14, 2026. The split reduced the number of outstanding shares from approximately 168.4 million to 16.8 million to adjust the per-share trading price on the Nasdaq Capital Market.
Vaxart's Board of Directors approved a new Director Stock Ownership Policy requiring non-employee directors to hold stock valued at two times their annual cash retainer. The Board also adopted a Director Resignation Policy requiring directors to tender their resignation if they receive more 'withhold' than 'for' votes in an uncontested election.
Lesaka Technologies increased the annual base salary for Group CFO Dan Smith to approximately $447,053 and established fiscal 2027 cash incentive award structures for four senior executives. The incentive awards for Messrs. Heilbron, Kola, Mali, and Smith are based on a mix of quantitative financial performance and qualitative objectives, with maximum potential payouts of 120% of their respective base salaries.
Stephen Bye resigned from the Board of Directors of Inseego Corp., effective September 30, 2026. His departure is due to his upcoming appointment as CEO of WW International, Inc. and is not the result of any disagreement with the company.
Smith Douglas Homes Insider Thomas L. Bradbury Buys $200K of Stock
Thomas L. Bradbury bought 19,360 shares of Smith Douglas Homes Corp. at $10.31 a share, worth $200K in total on Sep 10, 2026. Shares held after the trade: 78,278 (+32.9%).
Quicklogic Sr. VP and CTO Timothy Saxe Sells $164K of Stock
Timothy Saxe, Sr. VP and CTO, sold 15,190 shares of Quicklogic Corp at $10.80 a share, worth $164K in total on Sep 10, 2026. Shares held after the trade: 143,976 (-9.5%).
Teladoc Health CEO Charles Divita III Sells $109K of Stock
Charles Divita III, CEO, sold 17,805 shares of Teladoc Health, Inc. at $6.10 a share, worth $109K in total on Sep 11, 2026. Shares held after the trade: 465,535 (-3.7%).
Jeremy Skule, EVP, CSO, sold 1,125 shares of Nasdaq, Inc. at $94.22 a share, worth $106K in total on Sep 10, 2026. Shares held after the trade: 101,198 (-1.1%).
Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, a 60% increase year-over-year, driven by wearable cardioverter defibrillator (WCD) market expansion and competitive gains. The company reported a GAAP net loss of $44.1 million and increased its full-year fiscal 2027 revenue guidance to $141 million.
Term
Q1 2027
Earnings call
Sep 14, 2026, 4:30 PM ET
“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%. We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”
Quicklogic President and CEO Brian C. Faith Sells $273K of Stock
Brian C. Faith, President and CEO, sold 25,292 shares of Quicklogic Corp at $10.80 a share, worth $273K in total on Sep 10, 2026. Shares held after the trade: 255,791 (-9.0%).